Compare Ginkgo Bioworks Holdings Inc (DNA) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Eni SpA — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Eni SpA trades at $55.89 (market cap $79.81B). The key difference: Eni SpA is far larger — about 104.5× Ginkgo Bioworks Holdings Inc's market cap, and Eni SpA pays a 4.39% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Eni SpA for 53 Days on average.
| DNA | E | |
|---|---|---|
Market Cap | $763.64M | $79.81B |
Volume | 3,204,177 | 365,912 |
Sector | Health | Energy |
52-Week High | $15.83 | $57.61 |
52-Week Low | $5.48 | $34.03 |
Typical Hold Time | 7 Days | 53 Days |
Enterprise Value | $865.59M | $104.34B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Eni (E) trades at $56.00, up 3.78% with bullish technical signals from moving averages. The company shows stable cash flow generation despite revenue declines from $132.5B in 2022 to $82.2B in 2025. Recent developments include expansion into humanoid robotics and fuel discount initiatives. Valuation appears attractive with P/E of 12.87 and EV/EBITDA of 4.18, while analyst consensus leans neutral with 61.53% hold ratings.
The stock presents value opportunity with strong cash flows and dividend yield, but faces headwinds from volatile energy markets and recent earnings misses. Upside potential exists from new exploration projects in Venezuela and Indonesia, though execution risks and energy price sensitivity remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
